PL3394051T3 - Procedura krystalizacji do otrzymywania kryształów półwodnej kanagliflozyny - Google Patents

Procedura krystalizacji do otrzymywania kryształów półwodnej kanagliflozyny

Info

Publication number
PL3394051T3
PL3394051T3 PL16819899T PL16819899T PL3394051T3 PL 3394051 T3 PL3394051 T3 PL 3394051T3 PL 16819899 T PL16819899 T PL 16819899T PL 16819899 T PL16819899 T PL 16819899T PL 3394051 T3 PL3394051 T3 PL 3394051T3
Authority
PL
Poland
Prior art keywords
crystallization procedure
hemihydrate crystals
canagliflozin hemihydrate
obtaining
obtaining canagliflozin
Prior art date
Application number
PL16819899T
Other languages
English (en)
Inventor
Ruben De Keyser
Stijn LAPS
Thomas Joachim Landewald Rammeloo
Koen Johan Herman WEERTS
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of PL3394051T3 publication Critical patent/PL3394051T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
PL16819899T 2015-12-21 2016-12-20 Procedura krystalizacji do otrzymywania kryształów półwodnej kanagliflozyny PL3394051T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15201459 2015-12-21
EP16172070 2016-05-31
EP16819899.2A EP3394051B1 (en) 2015-12-21 2016-12-20 Crystallization procedure for obtaining canagliflozin hemihydrate crystals
PCT/EP2016/081861 WO2017108752A1 (en) 2015-12-21 2016-12-20 Crystallization procedure for obtaining canagliflozin hemihydrate crystals

Publications (1)

Publication Number Publication Date
PL3394051T3 true PL3394051T3 (pl) 2020-10-19

Family

ID=57681580

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16819899T PL3394051T3 (pl) 2015-12-21 2016-12-20 Procedura krystalizacji do otrzymywania kryształów półwodnej kanagliflozyny

Country Status (18)

Country Link
US (1) US10323025B2 (pl)
EP (1) EP3394051B1 (pl)
JP (1) JP6851379B2 (pl)
KR (1) KR102742900B1 (pl)
CN (1) CN108368096B (pl)
AU (1) AU2016376653B2 (pl)
CA (1) CA3006237C (pl)
CY (1) CY1124885T1 (pl)
DK (1) DK3394051T3 (pl)
EA (1) EA036793B1 (pl)
ES (1) ES2794909T3 (pl)
HR (1) HRP20200755T1 (pl)
HU (1) HUE049895T2 (pl)
LT (1) LT3394051T (pl)
PL (1) PL3394051T3 (pl)
PT (1) PT3394051T (pl)
SI (1) SI3394051T1 (pl)
WO (1) WO2017108752A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3148236A1 (en) 2019-07-22 2021-01-28 Canopy Growth Corporation Continuous crystallization of cannabinoids in a stirred-tank reactor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
LT2896397T (lt) 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
US20080046233A1 (en) * 2006-08-15 2008-02-21 Broadcom Corporation Packet Loss Concealment for Sub-band Predictive Coding Based on Extrapolation of Full-band Audio Waveform
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
KR101532412B1 (ko) * 2009-07-10 2015-06-29 얀센 파마슈티카 엔.브이. 1-(β-D-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법
CA2911261A1 (en) 2013-05-08 2014-11-13 Lek Pharmaceuticals D.D. Novel crystalline hydrates of 1-(.beta.-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
CZ305172B6 (cs) * 2014-03-28 2015-05-27 Bochemie A.S. Diskontinuální krystalizační jednotka pro výrobu kulovitých krystalů
CN103896930B (zh) * 2014-04-02 2016-08-17 安徽联创生物医药股份有限公司 卡格列净半水合物药用晶型的制备方法

Also Published As

Publication number Publication date
ES2794909T3 (es) 2020-11-19
JP6851379B2 (ja) 2021-03-31
CN108368096B (zh) 2021-12-10
JP2019504022A (ja) 2019-02-14
US20190002449A1 (en) 2019-01-03
KR20180095839A (ko) 2018-08-28
HUE049895T2 (hu) 2020-11-30
CA3006237A1 (en) 2017-06-29
AU2016376653A1 (en) 2018-06-07
WO2017108752A1 (en) 2017-06-29
CY1124885T1 (el) 2022-07-22
DK3394051T3 (da) 2020-07-20
AU2016376653B2 (en) 2020-07-30
EA201891470A1 (ru) 2018-12-28
SI3394051T1 (sl) 2020-07-31
EA036793B1 (ru) 2020-12-22
US10323025B2 (en) 2019-06-18
KR102742900B1 (ko) 2024-12-12
LT3394051T (lt) 2020-08-10
CA3006237C (en) 2023-10-03
CN108368096A (zh) 2018-08-03
PT3394051T (pt) 2020-06-08
EP3394051A1 (en) 2018-10-31
EP3394051B1 (en) 2020-04-22
HRP20200755T1 (hr) 2020-07-24

Similar Documents

Publication Publication Date Title
IL289910A (en) A method for preparing allulose crystals
SG10201913200XA (en) Crystalline form of lorlatinib free base
SG11201708793SA (en) Crystals of azabicyclic compound
IL246385B (en) Crystalline forms of efitinib di-malate
ZA201906464B (en) Crystalline forms of (s)-afoxolaner
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
SG10201911417PA (en) Crystalline compounds
IL262674A (en) crystals
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
PL3305770T3 (pl) Sposób wytwarzania postaci krystalicznej enzalutamidu
PL3529236T4 (pl) Krystaliczne formy erawacykliny
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
IL270961A (en) Crystalline form of N-butyldeoxygalactonogirimycin
IL253479A0 (en) Crystalline forms of efinconazole
IL259982A (en) Crystalline forms of thienopyrimidine compound
HUE049895T2 (hu) Kristályosítási eljárás kanagliflozin hemihidrát kristályok elõállítására
PT3395819T (pt) Forma cristalina de derivado de aminopirano substituído
PL3350179T3 (pl) Krystaliczne postacie
IL270937A (en) Crystalline forms of saltalicib
GB201619463D0 (en) Method for producing allulose crystals
GB201509928D0 (en) Process for preparation of carbohydrates